Literature DB >> 9248788

Multiple-dose pharmacokinetics of a long half-life drug: contributions of mathematical modeling.

J R Nedelman1, E Gibiansky, J Cramer, J Kovarik, J Meligeni, B Robbins.   

Abstract

A mathematical model was found that consistently described diverse pharmacokinetic data for a development compound from three pharmacokinetic studies in healthy volunteers and two efficacy and safety studies in patients. The model provided: quantification of demographic and random sources of pharmacokinetic variability; estimation of important pharmacokinetic parameters from sparse data; and explanation of observed patterns of pharmacokinetic response.

Entities:  

Mesh：

Year:  1997        PMID： 9248788     DOI： 10.1007/BF03189803

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN： 0378-7966            Impact factor:   2.441


  3 in total

Review 1.  Pharmacokinetics: philosophy of modeling.

Authors:  H Boxenbaum
Journal:  Drug Metab Rev       Date:  1992       Impact factor: 4.518

2.  Premarketing observational studies of population pharmacokinetics of new drugs.

Authors:  L B Sheiner; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

Review 3.  Population pharmacokinetics. Theory and clinical application.

Authors:  B Whiting; A W Kelman; J Grevel
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447
  3 in total
  1 in total

1.  Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.

Authors:  B R Yacyshyn; W Y Chey; J Goff; B Salzberg; R Baerg; A L Buchman; J Tami; R Yu; E Gibiansky; W R Shanahan
Journal:  Gut       Date:  2002-07       Impact factor: 23.059
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.